USPTO serial 87579575
BATTERSEA BIOTECH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- COWARD, JEFFERY
- Law office
- TMEG LAW OFFICE 106 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with BATTERSEA BIOTECH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
South San Francisco, CA
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of cancer and tumors; pharmaceutical preparations for the treatment of cancer and tumors via tumor antigen reactive T cells and Natural Killer cells; pharmaceutical preparations for the treatment of immune system related diseases and disorders; cells for medical or clinical use; kits comprised of cells and pharmaceuticals for medical or clinical use; pharmaceuticals for use in the treatment of infectious diseases and in cellular transplants; pharmaceutical preparations for immunotherapy, including T cell and Natural Killer cell therapy | ACTIVE | — |
| 009 | Scientific apparatus for priming and stimulating particular cells of the immune system for the treatment of cancer and autoimmune diseases and disorders | ACTIVE | — |
| 042 | Research and development of pharmaceuticals for the treatment of cancer and immune system-related diseases and disorders; clinical research in the field of cancer treatment and treatment of disorders related to the immune system; medical research services in the field of cancer, namely, priming and stimulating T cells and Natural Killer cells for research purposes | ACTIVE | — |
| 044 | Medical treatment services, namely, administration of gene therapy; medical and therapeutic services, namely, immunotherapy services comprising harvesting, transducing, or otherwise manipulating ex-vivo and re-administering blood cells | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Battersea Biotech, LLC
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named BATTERSEA BIOTECH
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 3, 2018 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 3, 2018 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 5, 2017 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Dec 5, 2017 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Dec 5, 2017 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Nov 27, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 28, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 25, 2017 | NWAP | NEW APPLICATION ENTERED | — |